Safety and Efficacy of Cefovecin (Convenia®) as an Adjunctive Treatment of Periodontal Disease in Dogs

DOI: 10.4236/ojvm.2012.23016   PDF   HTML     4,877 Downloads   10,693 Views   Citations

Abstract

This study was designed to determine the safety and efficacy of cefovecin (Convenia?; Pfizer Animal Health) when compared to clindamycin (Antirobe?; Pfizer Animal Health) as an adjunctive therapy to periodontal scaling or surgery for severe periodontal disease in dogs. A multi-centre, double-masked, randomised study was conducted in 299 dogs with severe periodontal disease. Clindamycin, administered once daily at 11 mg/kg bodyweight orally for 10 days following dental surgery was compared with a single, subcutaneous injection of cefovecin (8 mg/kg bodyweight) administered at the time of dental surgery. The primary efficacy parameter assessed was percentage of tooth-root sites bleeding when probed (an indicator of gingival inflammation) 42 days after surgery. Two-hundred and ninety-one (291) dogs were included in the efficacy assessments. Cefovecin was shown to be non-inferior to clindamycin. The percentage of sites bleeding on probing was reduced from 54.3% to 20.3% for the cefovecin group (53.1% reduced to 17.4% for the clindamycin group). There were no suspected adverse drug experiences attributed to treatment with cefovecin or clindamycin. Cefovecin was shown to be as effective and safe adjunctive treatment for severe periodontal disease in dogs undergoing periodontal scaling and surgery as clindamycin.

Share and Cite:

H. Giboin, C. Becskei, J. Civil and M. R. Stegemann, "Safety and Efficacy of Cefovecin (Convenia®) as an Adjunctive Treatment of Periodontal Disease in Dogs," Open Journal of Veterinary Medicine, Vol. 2 No. 3, 2012, pp. 89-97. doi: 10.4236/ojvm.2012.23016.

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1] C. Harvey, "Periodontal Disease in Dogs. Etiopathogenesis, Prevalence, and Significance", The Veterinary Clinics of North America. Small Animal Practice. Vol. 28, No. 5, 1998, 1111-1128. doi:10.1016/j.vetmic.2004.12.018
[2] J. Hardham, K. Dreier, J. Wong, C. Sfintescu and R. Evans, "Pigmented-Anaerobic Bacteria Associated with Canine Periodontitis", Veterinary Microbiology, Vol. 106, No. 1-2, 2005, 119-128. doi.org/10.1016/j.vetmic.2004.12.018
[3] P. Hennet and C. Harvey, "Aerobes in Periodontal Disease in the Dog: A Review", Journal of Veterinary Dentistry, Vol. 8, No. 1, 1991, 9-11.
[4] P. Hennet and C. Harvey, "Anaerobes in Periodontal Disease in the Dog: A Review", Journal of Veterinary Dentistry, Vol. 8, No. 2, 1991, 18-21.
[5] P. Hennet and C. Harvey, "Spirochetes in Periodontal Disease in the Dog: A Review", Journal of Veterinary Dentistry, Vol. 8, No. 3, 1991, 16-17.
[6] P. Hennet and C. Harvey, "Natural Development of Periodontal Disease in the Dog: A Review of Clinical, Anatomical and Histological Features", Journal of Veterinary Dentistry, Vol. 9, No. 3, 1992, 13-19.
[7] L. Forner, T. Larsen, M. Kilian and P. Holmstrup, "Incidence of Bacteremia after Chewing, Tooth Brushing and Scaling in Individuals with Periodontal Inflammation", Journal of Clinical Periodontology, Vol. 33, No. 6, 2006, 401-407. doi:10.1111/j.1600-051X.2006.00924.x
[8] M. Nieves, P. Hartwig, J. Kinyon and D. Riedesel, "Bacterial Isolates from Plaque and from Blood During and after Routine Dental Procedures in Dogs", Veterinary Surgery, Vol. 26, No. 1, 1997, 26-32. doi:10.1111/j.1532-950X.1997.tb01459.x
[9] H. Horz and G. Conrads, "Diagnosis and Anti-Infective Therapy of Periodontitis", Expert Review of Anti-Infective Therapy, Vol. 5, No. 4, 2007, 703-715. doi:10.1586/14787210.5.4.703
[10] L. DeBowes, D. Mosier, E. Logan, C. Harvey, S. Lowry and D. Richardson, "Association of Periodontal Disease and Histologic Lesions in Multiple Organs from 45 Dogs", Journal of Veterinary Dentistry, Vol. 13, No. 2, 1996, 57-60.
[11] Z. Pavlica, M. Petelin, P. Juntes, D. Erzen, D. Crossley and U. Skaleric, "Periodontal Disease Burden and Pathological Changes in Organs of Dogs." Journal of Veterinary Dentistry, Vol. 25, No. 2, 2008, 97-105.
[12] M. Jorgensen, A. Aalam and J. Slots, "Periodontal Antimicrobials-Finding the Right Solutions", International Dental Journal, Vol. 55, No. 1, 2005, 3-12.
[13] M. Addy and M. Martin, "Systemic Antimicrobials in the Treatment of Chronic Periodontal Diseases: A Dilemma", Oral Diseases, Vol. 9, 2003, 38-44. doi:10.1034/j.1601-0825.9.s1.7.x
[14] F. Sgolastra, R. Gatto, A. Petrucci and A. Monaco, "Effectiveness of Systemic Amoxicillin/Metronidazole as Adjunctive Therapy to Scaling and Root Planing in the Treatment of Chronic Periodontitis: A Systematic Review and Meta-Analysis", Journal of Periodontology, 2012, 1-22. doi:10.1902/jop.2012.110625
[15] A. Haffajee, S. Dibart, R. Kent and S. Socransky, "Clinical and Microbiological Changes Associated with the Use of 4 Adjunctive Systemically Administered Agents in the Treatment of Periodontal Infections", Journal of Clinical Periodontology, Vol. 22, No. 8, 1995, 618-627. doi:10.1111/j.1600-051X.1995.tb00815.x
[16] AVDC, 'Http://Www.Avdc.Org/Statements.Html [Accessed 07 February 2011]', in Policy Statement: The Use of Antibiotics in Veterinary Dentistry. 2005.
[17] J. Warrick, G. Inskeep, T. Yonkers, G. Stookey and T. Ewing, "Effect of Clindamycin Hydrochloride on Oral Malodor, Plaque, Calculus, and Gingivitis in Dogs with Periodontitis," Veterinary Therapeutics, Vol. 1, No. 1, 2000, 5-16.
[18] K. Zetner, G. Pum, W. Rausch, X. Rausch-Fan and S. Hung, "Effect of Clindamycin Hydrochloride on Gingival Crevicular Fluid and Immune Mediators in Beagles." Veterinary Therapeutics, Vol. 3, No. 2, 2002, 177-188.
[19] D. Nielsen, Walser, C., Kodan, G., Chaney, R.D., Yonkers, T., VerSteeg, J.D., Elfring, G., Slots, J., "Effects of Treatment with Clindamycin Hydrochloride on Progression of Canine Periodontal Disease after Ultrasonic Scaling", Veterinary Therapeutics, Vol. 1, No. 3, 2000, 150-158.
[20] M. R. Stegemann, J. Sherington and S. Blanchflower, "Pharmacokinetics and Pharmacodynamics of Cefovecin in Dogs", Journal of Veterinary Pharmacology and Therapeutics, Vol. 29, No. 6, 2006, 501-511. doi:10.1111/j.1365-2885.2006.00801.x
[21] R. Six, J. Cherni, R. Chesebrough, D. Cleaver, C. J. Lindeman, G. Papp, et al., "Efficacy and Safety of Cefovecin in Treating Bacterial Folliculitis, Abscesses, or Infected Wounds in Dogs", Journal of the American Veterinary Medical Association, Vol. 233, No. 3, 2008, 433-439. doi:10.2460/javma.233.3.433
[22] M. R. Stegemann, N. Coati, C. A. Passmore and J. Sherington, "Clinical Efficacy and Safety of Cefovecin in the Treatment of Canine Pyoderma and Wound Infections", The Journal of Small Animal Practice. Vol. 48, No. 7, 2007, 378-386. doi:10.1111/j.1748-5827.2007.00363.x
[23] M. R. Stegemann, J. Sherington and C. Passmore, "The Efficacy and Safety of Cefovecin in the Treatment of Feline Abscesses and Infected Wounds", The Journal of Small Animal Practice. Vol. 48, No. 12, 2007, 683-689. doi:10.1111/j.1748-5827.2007.00390.x
[24] R. Six, D. M. Cleaver, C. J. Lindeman, J. Cherni, R. Chesebrough, G. Papp, et al., "Effectiveness and Safety of Cefovecin Sodium, an Extended-Spectrum Injectable Cephalosporin, in the Treatment of Cats with Abscesses and Infected Wounds", Journal of the American Veterinary Medical Association, Vol. 234, No. 1, 2009, 81-87. doi:10.2460/javma.234.1.81
[25] C. A. Passmore, J. Sherington and M. R. Stegemann, "Efficacy and Safety of Cefovecin (Convenia) for the Treatment of Urinary Tract Infections in Dogs", The Journal of Small Animal Practice. Vol. 48, No. 3, 2007, 139-144. doi:10.1111/j.1748-5827.2006.00231.x
[26] C. A. Passmore, J. Sherington and M. R. Stegemann, "Efficacy and Safety of Cefovecin for the Treatment of Urinary Tract Infections in Cats", The Journal of Small Animal Practice. Vol. 49, No. 6, 2008, 295-301. doi:10.1111/j.1748-5827.2008.00545.x
[27] VICH, ' International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products'. 2000.
[28] C. Harvey, L. Laster, F. Shofer and B. Miller, "Scoring the Full Extent of Periodontal Disease in the Dog: Development of a Total Mouth Periodontal Score (Tmps) System." Journal of Veterinary Dentistry, Vol. 25, No. 3, 2008, 176-180.
[29] EMEA, 'Http://Www.Ema.Europa.Eu/Ema/ Doc_Index.Jsp?Curl=Pages/Includes/ Document/Document_Detail.Jsp?Webcontentid =Wc500097081&Murl=Menus/Document_Library/ Document_Library.Jsp&Mid=0b01ac058009a3dc [Accessed 19 April 2012]', in Guidelines on statistical principles for veterinary clinical trials. 2000.
[30] M. Stegemann, C. Passmore, J. Sherington, C. Lindeman, G. Papp, D. Weigel, et al., "Antimicrobial Activity and Spectrum of Cefovecin, a New Extended- Spectrum Cephalosporin, against Pathogens Collected from Dogs and Cats in Europe and North America", Antimicrobial Agents and Chemotherapy, Vol. 50, No. 7, 2006, 2286-2292. doi:10.1128/AAC.00077-06
[31] C.E. Harvey, C. Thornsberry, B.R. Miller and F.S Shofer, "Antimicrobial Susceptibility of Subgingival Bacterial Flora in Dogs with Gingivitis." Journal of Veterinary Dentistry. Vol. 12, No. 4, 1995, 151-155.
[32] M. Radice, P.A. Martino and A.M. Reiter, "Evaluation of Subgingival Bacteria in the Dog and Susceptibility to Commonly Used Antibiotics", Journal of Veterinary Dentistry, Vol. 23, No. 4, 2006, 219-224.

  
comments powered by Disqus

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.